Development of anticancer therapy with GGCT targeting siRNA for urothelial tumor

2014 Fiscal Year Final Research Report

• Project/Area Number: 24592384
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Urology
• Research Institution: Shiga University of Medical Science
• Principal Investigator: KAGEYAMA Susumu 滋賀医科大学, 医学部, 講師 (50378452)
• Co-Investigator(Kenkyū-buntansha): HANADA Eiki 滋賀医科大学, 医学部, 助教 (40555067) ; ARAKI Isao 滋賀医科大学, 医学部, 客員教授 (50252424) ; YOSHIKI Tatsuhiro 滋賀医科大学, 医学部, 客員教授 (80230704)
• Research Collaborator: KAWAUCHI Akihiro 滋賀医科大学, 医学部, 教授 (90240952)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Keywords: γ-グルタミルシクロトランスフェラーゼ / RNA干渉 / 尿路上皮癌

Outline of Final Research Achievements

We evaluated a utility of GGCT targeting therapy with RNAi for urothelial cancer.
In immunohistochemical analysis of surgical specimens of non-muscle invasive bladder cancer, high expression was revealed in 64% of the patients. The five-year recurrence free survivals of high and low-no GGCT expression groups were 30% and 57%, respectively. Significant antiprolifelative effect via GGCT targeting siRNA was shown in UMUC-3 cells, and combination treatment consisting of Adriamycin and GGCT siRNA reduced cell viability more than the treatment with Adriamycin alone. According to our results, GGCT can be a useful treatment target with RNAi for urothelial cancer. We continue the treatment experiment of tumor-bearing mice by administration GGCT siRNA, and evaluate therapeutic effects and adverse events.

Free Research Field

泌尿器癌